SK08 / Zhiyi Biotech - LARVOL DELTA

A Phase 2 Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patients with Active Mild to Moderate Ulcerative Colitis (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Guangzhou Zhiyi Biotechnology Co., Ltd. | Trial completion date: Aug 2025 ➔ Aug 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2027

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

A Phase 2 Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patients with Active Mild to Moderate Ulcerative Colitis (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Guangzhou Zhiyi Biotechnology Co., Ltd.

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D (clinicaltrials.gov) - P3 | N=1298 | Recruiting | Sponsor: Guangzhou Zhiyi Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder

A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D (clinicaltrials.gov) - P3 | N=1298 | Not yet recruiting | Sponsor: Guangzhou Zhiyi Biotechnology Co., Ltd.

New P3 trial • Gastrointestinal Disorder